Back to Journals » Journal of Pain Research » Volume 9

Can we not work together to help family practitioners become more effective pain managers?

Authors Fudin J, Atkinson TJ, Raouf M, Schatman ME

Received 4 September 2016

Accepted for publication 5 September 2016

Published 13 October 2016 Volume 2016:9 Pages 803—806

DOI https://doi.org/10.2147/JPR.S121505

Checked for plagiarism Yes

Editor who approved publication: Prof. Dr. Enrica Santarcangelo

Jeffrey Fudin,1,2,3 Timothy J Atkinson,4 Mena Raouf,4 Michael E Schatman5

1Stratton VA Medical Center, Albany, NY, USA; 2Albany College of Pharmacy and Health Sciences, Albany, NY, USA; 3Scientific and Clinical Affairs, Remitigate LLC, Delmar, NY, USA; 4VA Tennessee Valley Healthcare System, Murfreesboro, Nashville, TN, USA; 5US Pain Foundation, Bellevue, WA, USA


Snyder et al recently published a review in American Family Physician titled, “Treating Painful Diabetic Peripheral Neuropathy: An Update”, which provided an overview of pharmacologic treatment options for providers; however, some of the recommendations made by the authors were concerning.1 Recommendations that caught our attention included statements around pregabalin adjustment for renal impairment, using selective serotonin reuptake inhibitors (SSRIs) in the treatment of diabetic peripheral neuropathy (DPN), classification of tramadol, tapentadol, and oxycodone in DPN.


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author:

OxyContin was submitted and justifiably approved by the agency as a 12-hour dosage form

Fudin J, Raouf M, Wegrzyn EL

Journal of Pain Research 2016, 9:609-612

Published Date: 7 September 2016